Cargando…

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma

BACKGROUND: Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are candidates for surgery at the time of diagnosis. Thus, there is a great global unmet need for valuable biomarkers that cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ying-Ying, Guo, Kai, Zhao, Rui, Li, Yuan, Lv, Xiao-Jing, Lu, Zi-Peng, Tian, Lei, Ren, Shuai, Wang, Zhong-Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259126/
https://www.ncbi.nlm.nih.gov/pubmed/37312938
http://dx.doi.org/10.1177/20552076231179007
_version_ 1785057601914929152
author Cao, Ying-Ying
Guo, Kai
Zhao, Rui
Li, Yuan
Lv, Xiao-Jing
Lu, Zi-Peng
Tian, Lei
Ren, Shuai
Wang, Zhong-Qiu
author_facet Cao, Ying-Ying
Guo, Kai
Zhao, Rui
Li, Yuan
Lv, Xiao-Jing
Lu, Zi-Peng
Tian, Lei
Ren, Shuai
Wang, Zhong-Qiu
author_sort Cao, Ying-Ying
collection PubMed
description BACKGROUND: Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are candidates for surgery at the time of diagnosis. Thus, there is a great global unmet need for valuable biomarkers that could improve the opportunity to detect PDAC at the resectable stage. This study aimed to develop a potential biomarker model for the detection of resectable PDAC by tissue and serum metabolomics. METHODS: Ultra-high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS/MS) was performed for metabolome quantification in 98 serum samples (49 PDAC patients and 49 healthy controls (HCs)) and 20 pairs of matched pancreatic cancer tissues (PCTs) and adjacent noncancerous tissues (ANTs) from PDAC patients. Univariate and multivariate analyses were used to profile the differential metabolites between PDAC and HC. RESULTS: A total of 12 differential metabolites were present in both serum and tissue samples of PDAC. Among them, a total of eight differential metabolites showed the same expressional levels, including four upregulated and four downregulated metabolites. Finally, a panel of three metabolites including 16-hydroxypalmitic acid, phenylalanine, and norleucine was constructed by logistic regression analysis. Notably, the panel was capable of distinguishing resectable PDAC from HC with an AUC value of 0.942. Additionally, a multimarker model based on the 3-metabolites-based panel and CA19-9 showed a better performance than the metabolites panel or CA19-9 alone (AUC: 0.968 vs. 0.942, 0.850). CONCLUSIONS: Taken together, the resectable early-stage PDAC has unique metabolic features in serum and tissue samples. The defined panel of three metabolites has the potential value for early screening of PDAC at the resectable stage.
format Online
Article
Text
id pubmed-10259126
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102591262023-06-13 Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma Cao, Ying-Ying Guo, Kai Zhao, Rui Li, Yuan Lv, Xiao-Jing Lu, Zi-Peng Tian, Lei Ren, Shuai Wang, Zhong-Qiu Digit Health Original Research BACKGROUND: Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are candidates for surgery at the time of diagnosis. Thus, there is a great global unmet need for valuable biomarkers that could improve the opportunity to detect PDAC at the resectable stage. This study aimed to develop a potential biomarker model for the detection of resectable PDAC by tissue and serum metabolomics. METHODS: Ultra-high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS/MS) was performed for metabolome quantification in 98 serum samples (49 PDAC patients and 49 healthy controls (HCs)) and 20 pairs of matched pancreatic cancer tissues (PCTs) and adjacent noncancerous tissues (ANTs) from PDAC patients. Univariate and multivariate analyses were used to profile the differential metabolites between PDAC and HC. RESULTS: A total of 12 differential metabolites were present in both serum and tissue samples of PDAC. Among them, a total of eight differential metabolites showed the same expressional levels, including four upregulated and four downregulated metabolites. Finally, a panel of three metabolites including 16-hydroxypalmitic acid, phenylalanine, and norleucine was constructed by logistic regression analysis. Notably, the panel was capable of distinguishing resectable PDAC from HC with an AUC value of 0.942. Additionally, a multimarker model based on the 3-metabolites-based panel and CA19-9 showed a better performance than the metabolites panel or CA19-9 alone (AUC: 0.968 vs. 0.942, 0.850). CONCLUSIONS: Taken together, the resectable early-stage PDAC has unique metabolic features in serum and tissue samples. The defined panel of three metabolites has the potential value for early screening of PDAC at the resectable stage. SAGE Publications 2023-05-31 /pmc/articles/PMC10259126/ /pubmed/37312938 http://dx.doi.org/10.1177/20552076231179007 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Cao, Ying-Ying
Guo, Kai
Zhao, Rui
Li, Yuan
Lv, Xiao-Jing
Lu, Zi-Peng
Tian, Lei
Ren, Shuai
Wang, Zhong-Qiu
Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title_full Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title_fullStr Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title_full_unstemmed Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title_short Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
title_sort untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259126/
https://www.ncbi.nlm.nih.gov/pubmed/37312938
http://dx.doi.org/10.1177/20552076231179007
work_keys_str_mv AT caoyingying untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT guokai untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT zhaorui untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT liyuan untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT lvxiaojing untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT luzipeng untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT tianlei untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT renshuai untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma
AT wangzhongqiu untargetedmetabolomicscharacterizationoftheresectablepancreaticductaladenocarcinoma